Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$66.75 USD

66.75
3,261,118

+0.52 (0.79%)

Updated Nov 11, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.

Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

by Kevin Cook

This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies

Edwards Lifesciences Recalls Heart Device on Balloon Rupture

by Zacks Equity Research

Shares of Edwards Lifesciences (EW) decline post product recall news.

Urmimala Biswas headshot

CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?

by Urmimala Biswas

While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

DexCom and Companion Medical Collaboration to Support CGM

by Zacks Equity Research

The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.

Why Is Edwards Lifesciences (EW) Down 2.9% Since Last Earnings Report?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HOLX vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

by Kevin Cook

This $4 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies

Masimo Gets CE Mark for ANI Module, Enhances Root Platform

by Zacks Equity Research

Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.

Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised

by Zacks Equity Research

Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.

Edwards Lifesciences Takes Over CAS Medical Systems for $100M

by Zacks Equity Research

This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.

What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.

Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Retail Pharmacy USA Lift Walgreens' (WBA) Q2 Earnings?

by Zacks Equity Research

Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.

Sweta Killa headshot

Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for JHMM

Edwards Lifesciences Presents Positive Partner 3 Trial Data

by Zacks Equity Research

Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

by Zacks Equity Research

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

Tracey Ryniec headshot

NASH, Allergies and Beauty Stocks: Invest or Not?

by Tracey Ryniec

There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?

Medtronic (MDT) Releases Encouraging Evalut TAVR Result

by Zacks Equity Research

Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.

Edwards Lifesciences (EW) Looks Good: Stock Adds 6.2% in Session

by Zacks Equity Research

Edwards Lifesciences (EW) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Company News For Mar 19, 2019

by Zacks Equity Research

Companies in the news are: OSTK, FIS, WP, EW and DERM

Edwards Lifesciences Makes Investments in Heart Failure Space

by Zacks Equity Research

The two transactions align with Edwards Lifesciences' (EW) goal of making the most innovative medical care available to patients of structural heart disease.

Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

by Zacks Equity Research

The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.